Joseph Limber will resign as president and chief executive officer of Aclara BioSciences of Mountain View, Calif., the company said last week. Limber is leaving, effective Dec. 1, to pursue other opportunities, the company said in a statement. He will remain as a member of the company’s board of directors and will assist in recruiting a new CEO. He served for five years.
Edward Hurwitz of Alta Partners, a life sciences and technology venture capital firm, and the former CFO of Affymetrix, will serve as executive director.
In other changes at the company, Sharat Singh, vice president of advanced technologies, has been named senior vice president of the company’s eTag assay technology. Singh received his PhD in organic chemistry from the Indian Institute of Sciences and had a post-doctoral fellowship at Columbia University.
Dennis Harris, senior vice president, research and development, was named senior vice president of systems integration and business development. Before joining Aclara in 2001, Harris held a number of positions at Amersham International and was responsible for the development of products and technologies in DNA labeling and detection, hybridization, gene expression, and DNA sequencing. Harris holds a PhD in biochemistry from the University of Sussex, England.
Dawn Madden, director of marketing, was named vice president of marketing. Madden came to Aclara in April 2002 from Applied Biosystems where she managed the genomic applications marketing group. Previously, she held various product management and business development positions at Agilent and Amersham Biosciences. She holds an MBA from Santa Clara University and a B.S. in Biochemistry from the University of California, Riverside.
David Vendertie has joined gene expression and gene therapy service provider Althea Technologies of San Diego as vice president and chief financial officer and Josephe Monforte joins as vice president and chief scientific officer, the company said last week.
Vandertie joins Althea from Syngenta, Genomic Research and Technology (formerly an agribusiness of Novartis), where he was the director of finance and purchasing. Prior to his service at Syngenta, he was the corporate controller at Quidel Corporation and The Immune Response Corporation. He received his BBA in accounting from the University of Wisconsin, Whitewater.
As chief scientific officer, Monforte will be responsible for assisting with the strategic planning for Althea, in particular, the advancement of a gene expression analysis technology that was developed under his direction, and acquired by Althea from GeneTrace Systems in December 2001. Monforte’s experience includes cofounding GeneTrace Systems, where he served as its chief scientific officer for seven years, and being a project leader at the Department of Energy Joint Genome Institute, where he managed the DOE’s human genome project and the DNA sequencing efforts related to the multiagency counter-bioterrorism program. He has held positions as staff scientist in toxicology at SRI International and visiting professor of chemistry at the University of California at Berkeley, where he received his PhD in biophysical chemistry.